Table 1.
Laboratory findings from 8 weeks before combination therapy of pulse glucocorticoids with cyclophosphamide to 52 weeks later
| −8 weeks | −1 weeks | 0 weeks | 2 weeks | 3 weeks | 4 weeks | 6 weeks | 12 weeks | 26 weeks | 32 weeks | 52 weeks | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FBG (mmol/L) | 13 | 14.9 | 16.2 | 15.1 | 8.6 | 4.4 | 3.8 | 4.0 | 4.4 | 4.3 | 5.33 |
| 2hPBG (mmol/L) | 22 | 19.2 | 25.5 | 25.5 | 16.6 | 14.5 | 6.0 | 5.8 | 6.2 | 6.0 | 5.6 |
| Urine ketone (mmol/L) | 3.9 | ≥7.8 | NEG | NEG | NEG | NEG | NEG | NEG | NEG | NEG | |
| HbA1c, % (4.5–6.3) | 10.1 | 9.1 | 5.2 | 5.1 | 5.1 | ||||||
| Fasting INS, uIU/mL (5.2–17.2) | >300 | 647.27 | 392.97 | 43.43 | 12.95 | 7.88 | 11.80 | 9.50 | |||
| C‐peptide, ng/mL (0.8–4.2) | 6.6 | 1.55 | 2.09 | ||||||||
| INS infusion (unit/day) | 972 | 480 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral antidiabetic agents | 4 | 3 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Testosterone (ng/mL) | 0.92 | 0.29 | 0.0 | <0.1 | <0.1 | ||||||
| ANA | +S1:1280 | +S 1:1280 | |||||||||
| Ro52 | ++++165 | +++150 | |||||||||
| RNP | ++++138 | +++106 | |||||||||
| SSA | ++++72 | +++72 | |||||||||
| C3, g/L (0.73–1.46) | 0.517 | 0.428 | 0.941 | 0.866 | 0.910 | ||||||
| C4, g/L (0.1–0.4) | 0.088 | 0.088 | 0.117 | 0.096 | 0.101 | ||||||
| ESR (mm/h) | 23 | 26 | 8 | ||||||||
| PA, mg/L (200–400) | 70 | 119 | 274 | 254 | 231 | ||||||
| Wt (kg) | 57 | 48 | 45.7 | 65 | 72 |
2hPBG, 2‐h plasma blood glucose; ANA, antinuclear antibody; ESR, erythrocyte sendimentation rate; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; INS, insulin; NEG, negative; PA, prealbumin; RNP, antiribonucleoprotein antibody; SSA, anti‐SSA antibody; Wt, weight.